Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals

Familial combined hyperlipidemia (FCHL) is an inherited disorder characterized by elevated levels of cholesterol and triglycerides; it often occurs in Mexican individuals with coronary heart disease (CHD). The purpose of this study is to identify the specific genes that predispose Mexican individuals to FCHL.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperlipidemia, Familial Combined Cardiovascular Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Coronary Disease Dyslipidemias Genetic Diseases, Inborn Heart Diseases Hyperlipidemias Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Metabolic Diseases Metabolism, Inborn Errors Myocardial Ischemia Nutritional and Metabolic Diseases Vascular Diseases

Age range

10 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Instituto Nacional De Ciencias Medicas y Nutricion

Mexico City, 14000, Mexico

About this study

CHD is the leading cause of death in Mexico. Dyslipidemia that is characterized by high total cholesterol, high triglycerides, and low "good" high-density lipoprotein (HDL) cholesterol is a risk factor for developing CHD. Research has shown that the Mexican population has an increased tendency towards dyslipidemia, but it is not known what genetic factors contribute to this predisposition. This study will examine the genetic basis of FCHL, which is an inherited form of dyslipidemia characterized by elevated levels of total cholesterol and triglycerides. FCHL is a major contributing factor in CHD; 20% of individuals with CHD under the age of 60 have FCHL. The purpose of this study is to identify and characterize the specific DNA sequence variations that predispose Mexican individuals to FCHL. Results of this study may aid in the development of appropriate prevention and screening techniques.

This study will enroll individuals in Mexico who have FCHL. Participants will attend one study visit for blood collection and DNA sampling. Family members of participants will be contacted and asked to provide a DNA sample also. A select group of participants will return for a second study visit for RNA sampling. Study researchers will analyze participants' DNA and RNA samples, as well as two FCHL genes identified in previous research studies.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Elevated levels of serum total cholesterol, triglycerides, or both
Elevated levels of serum apolipoprotein B (using the Mexican population percentiles)

Exclusion criteria

Tendon xanthomas
Kidney disease
Thyroid disorder

Treatment and study plan

Primary outcomes

Identifying the specific genes that predispose Mexican individuals to FCHL

Time frame: Measured through the use of genetic samples

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Official study title

Genetic Susceptibility to Common Lipid Disorders in Mexico

Important dates

Study start: 2006
Primary completion: 2011
Study completion: 2011
First posted: Aug 17, 2006
Registry last updated: Jan 12, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed